Erratum: More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1 (eLife, (2016) 5, 10.7554/eLife.10670);More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1

eLife

Volumn 5, Issue FEBRUARY2016, 2016, Pages

  Feder, Alison F ^a   Rhee, Soo Yon ^b   Holmes, Susan P ^a   Shafer, Robert W ^b   Petrov, Dmitri A ^a   Pennings, Pleuni S ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b Stanford Medicine Children s Health   (United States)

^c SAN FRANCISCO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STATISTICAL PARAMETERS; ADAPTATION; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETIC SELECTION; GENOTYPE; HIV INFECTIONS; MUTATION RATE; VIROLOGY;

ADAPTATION, BIOLOGICAL; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION RATE; SELECTION, GENETIC;

EID: 84979609816     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.24879     Document Type: Erratum

References (46)

1. Alexander HK, Martin G, Martin OY, Bonhoeffer S. 2014. Evolutionary rescue: linking theory for conservation and medicine. Evolutionary Applications 7: 1161-1179. doi: 10.1111/eva.12221
2. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. 2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PloS One 4: e4724. doi: 10.1371/journal.pone.0004724
3. Cong ME, Heneine W, García-Lerma JG. 2007. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. Journal of Virology 81: 3037-3041. doi: 10.1128/JVI.02712-06
4. Cook LM, Grant BS, Saccheri IJ, Mallet J. 2012. Selective bird predation on the peppered moth: the last experiment of michael majerus. Biology Letters 8: 609-612. doi: 10.1098/rsbl.2011.1136
5. Core Team R. 2013. A Language & Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
6. Daborn P, Boundy S, Yen J, Pittendrigh B, ffrench-Constant R. 2001. DDT resistance in correlates with over- expression and confers cross-resistance to the neonicotinoid imidacloprid. Molecular Genetics and Genomics 266: 556-563. doi: 10.1007/s004380100531
7. Darwin C. 1859. On the Origin of Species by Means of Natural Selection. Murray, London.
8. Department of Health & Human Services. Panel on antiretroviral guidelines for adults & adolescents. guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at http://aidsinfo.nih. gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. section accessed 2015-04-10.
9. Dunn DT, Coughlin K, Cane PA. 2011. Genotypic resistance testing in routine clinical care. Current Opinion in HIV and AIDS 6: 251--257. doi: 10.1097/COH.0b013e32834732e8
10. Fournier DA, Skaug HJ, Ancheta J, Ianelli J, Magnusson A, Maunder MN, Nielsen A, Sibert J. 2012. 04/01 AD model builder: using automatic differentiation for statistical inference of highly parameterized complex nonlinear models. Optimization Methods & Software 27: 233-249. doi: 10.1080/10556788.2011.597854
11. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS. ESS30009 StudyESS30009 Study. 2005. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. The Journal of Infectious Diseases 192: 1921--1930. doi: 10.1086/498069
12. Gonzalez LM, Brindeiro RM, Aguiar RS, Pereira HS, Abreu CM, Soares MA, Tanuri A. 2004. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype b and c proteases. Antimicrobial Agents and Chemotherapy 48: 3552-3555. doi: 10.1128/AAC.48.9.3552-3555.2004
13. Grandell J. 1997. Chapman & Hall/CRC Monographs on Statistics & Applied Probability. Mixed Poisson Processes. Taylor & Francis.
14. Jackman S. 2015. Pscl: Classes and Methods for R Developed in the Political Science Computational Laboratory, Stanford University. Stanford, California: Department of Political Science, Stanford University. R package version 1.4.9.
15. Juno J, Tuff J, Choi R, Card C, Kimani J, Wachihi C, Koesters-Kiazyk S, Ball TB, Farquhar C, Plummer FA, John-Stewart G, Luo M, Fowke KR. 2012. The role of g protein gene GNB3 C825T polymorphism in HIV-1 acquisition, progression and immune activation. Retrovirology 9: 1-14. doi: 10.1186/1742-4690-9-1
16. Kaplan NL, Hudson RR, Langley CH. 1989. The "hitchhiking effect" revisited. Genetics 123: 887--899.
17. Karasov T, Messer PW, Petrov DA. 2010. Evidence that adaptation in drosophila is not limited by mutation at single sites. PLoS Genetics 6: e1000924. doi: 10.1371/journal.pgen.1000924
18. Khanlou H, Yeh V, Guyer B, Farthing AC. 2005. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care and STDs 19: 135-140. doi: 10.1089/apc.2005.19.135
19. Kouyos RD, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Rauch A, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard HF.Swiss HIV Cohort Study. 2011. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clinical Infectious Diseases 52: 532-539. doi: 10. 1093/cid/ciq164
20. Laehnemann D, Peña-Miller R, Rosenstiel P, Beardmore R, Jansen G, Schulenburg H. 2014. Genomics of rapid adaptation to antibiotics: convergent evolution and scalable sequence amplification. Genome Biology and Evolution 6: 1287-1301. doi: 10.1093/gbe/evu106
21. Larder BA, Darby G, Richman DD. 1989. HIV with reduced sensitivity to zidovudine (aZT) isolated during prolonged therapy. Science 243: 1731-1734.
22. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNAsequencing. Nature 365: 671-673. doi: 10.1038/365671a0
23. Lee FJ, Amin J, Carr A. 2014. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks’ follow-up. PloS One 9: e97482. doi: 10.1371/journal.pone.0097482
24. Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR, AIDS Clinical Trials Group A5197 Study Team. 2012. Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption. JAIDS Journal of Acquired Immune Deficiency Syndromes 61: 19-22. doi: 10.1097/QAI.0b013e318264460f
25. Lopes PC, Sucena E, Santos ME, Magalhães S. 2008. Rapid experimental evolution of pesticide resistance in c. elegans entails no costs and affects the mating system. PloS One 3: e3741. doi: 10.1371/journal.pone.0003741
26. Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, Mallolas J, Miró JM, Gatell JM, Ribas J. 2008. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Research and Human Retroviruses 24: 1263--1268. doi: 10.1089/aid. 2008.0141
27. Mesplède T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22. doi: 10.1186/1742-4690-10-22
28. Meyer D, Zeileis A, Hornik K. 2015. Vcd: Visualizing Categorical Data. R Package Version 1: 4.
29. Moreno-Gamez S, Hill AL, Rosenbloom DIS, Petrov DA, Nowak MA, Pennings PS. 2015. Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance. Proceedings of the National Academy of Sciences of the United States of America 112: E2874-E2883. doi: 10.1073/pnas. 1424184112
30. Nair S, Nash D, Sudimack D, Jaidee A, Barends M, Uhlemann A-C, Krishna S, Nosten F, Anderson TJC. 2007. Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites. Molecular Biology and Evolution 24: 562-573. doi: 10.1093/molbev/msl185
31. Palumbi SR. 2001. Humans as the world’s greatest evolutionary force. Science 293: 1786-1790. doi: 10.1126/science.293.5536.1786
32. Pennings PS, Hermisson J. 2006. Soft sweeps III: the signature of positive selection from recurrent mutation. PLoS Genetics 2: e186. doi: 10.1371/journal.pgen.0020186
33. Pennings PS, Kryazhimskiy S, Wakeley J. 2014. Loss and recovery of genetic diversity in adapting populations of HIV. PLoS Genetics 10: e1004000.. doi: 10.1371/journal.pgen.1004000
34. Piatak M, Saag M, Yang L, Clark S, Kappes J, Luk K, Hahn B, Shaw G, Lifson J. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259: 1749-1754. doi: 10.1126/science.8096089
35. Politis DN, Romano JP, Wolf M. 1999. Subsampling. Springer Series in Statistics. New York: Springer.
36. Poon AF, Kosakovsky Pond SL, Bennett P, Richman DD, Leigh Brown AJ, Frost SD. 2007. Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis c virus. PLoS Pathogens 3: e45. doi: 10.1371/journal.ppat.0030045
37. Rabi SA, Laird GM, Durand CM, Laskey S, Shan L, Bailey JR, Chioma S, Moore RD, Siliciano RF. 2013. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. The Journal of Clinical Investigation 123: 3848-3860. doi: 10.1172/JCI67399
38. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 31: 298-303. doi: 10.1093/nar/gkg100
39. Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA. 2001. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. Journal of Clinical Microbiology 39: 1522-1529. doi: 10.1128/JCM.39.4.1522-1529.2001
40. Shuter J. 2008. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. The Journal of Antimicrobial Chemotherapy 61: 769-773. doi: 10.1093/jac/dkn020
41. Smith JM, Haigh J. 1974. The hitch-hiking effect of a favourable gene. Genetical Research 23: 23-35. doi: 10. 1017/S0016672300014634
42. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. study 006 team. The New England Journal of Medicine 341: 1865-1873. doi: 10.1056/NEJM199912163412501
43. Stearns SC, Koella JC. 2007. Evolution in health and disease. Oxford: OUP Oxford.
44. Tang MW, Shafer RW. 2012. HIV-1 antiretroviral resistance. Drugs 72: e1-e25. doi: 10.2165/11633630-000000000-00000
45. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E.M98-863 Study TeamM98-863 Study Team. 2002. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. The New England Journal of Medicine 346: 2039--2046. doi: 10.1056/NEJMoa012354
46. Zheng DP, Rodrigues M, Bile E, Nguyen DB, Diallo K, DeVos JR, Nkengasong JN, Yang C. 2013. Molecular characterization of ambiguous mutations in HIV-1 polymerase gene: implications for monitoring HIV infection status and drug resistance. PloS One 8: e77649. doi: 10.1371/journal.pone.0077649